Astrana Health, Inc.
ASTH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.16 | 0.99 | -0.81 | 0.92 |
| FCF Yield | 2.94% | 2.19% | 4.45% | 1.59% |
| EV / EBITDA | 11.89 | 14.86 | 11.35 | 31.68 |
| Quality | ||||
| ROIC | 5.50% | 7.37% | 6.70% | 7.69% |
| Gross Margin | 13.34% | 15.50% | 17.43% | 22.97% |
| Cash Conversion Ratio | 1.05 | 1.18 | 1.80 | 1.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 21.15% | 21.46% | 45.66% | 11.35% |
| Free Cash Flow Growth | 11.26% | -32.93% | 15.80% | 13.58% |
| Safety | ||||
| Net Debt / EBITDA | 1.29 | 0.22 | -0.52 | -0.32 |
| Interest Coverage | 2.70 | 5.25 | 13.16 | 18.20 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 55.13 | 36.06 | 34.15 | 43.46 |